<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01912716</url>
  </required_header>
  <id_info>
    <org_study_id>PEP INDO 2013</org_study_id>
    <secondary_id>ACG-CR-002-2013</secondary_id>
    <nct_id>NCT01912716</nct_id>
  </id_info>
  <brief_title>Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis</brief_title>
  <official_title>Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients: Searching for the Optimal Dose. A Prospective, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aurora Health Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is now established that indomethacin, a non-steroidal anti-inflammatory drug, at a dose of
      100 mg, is effective in reducing the frequency and severity of pancreatitis (inflammation of
      the pancreas) after endoscopic retrograde cholangiopancreatography (ERCP) in high risk
      patients. However, the optimal dose required is not known. The purpose of this study is to
      determine whether a dose of 200 mg, administered as rectal suppositories, is more effective
      than the standard dose of 100 mg. An ERCP procedure is a scope procedure where a lighted tube
      with a camera is passed down the patient's throat and allows for evaluation of the bile duct
      and/or pancreatic duct. The most common side effect of this procedure is post-ERCP
      pancreatitis, or swelling of the pancreas. Some patients are at higher risk for this
      complication than others. Our hypothesis is to compare the efficacy of these two dose
      regimens (100 mg vs 200 mg) of prophylactic rectally-administered indomethacin on the
      frequency and severity of post-ERCP pancreatitis in high-risk patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining informed consent, subjects will undergo ERCP per clinical protocol. All
      procedure-related clinical decisions and interventions will be dictated by the performing
      physician as he or she sees fit. At the end of the procedure, it will be determined by the
      endoscopist and research coordinator whether the patient meets inclusion criteria. If
      inclusion criteria are met, subjects will be randomized by concealed allocation to receive
      either 100mg or 150mg indomethacin, in the form of two or three 50mg rectal suppositories.
      Those patients who are randomized to receive the 100mg dose will receive an additional
      glycerin suppository. Four hours later, those patients who were randomized to the high-dose
      group will then receive an additional 50mg suppository while in the recovery area. At this
      same time point, subjects who were randomized to the standard-dose group, will receive a
      glycerin suppository in the recovery area. All participating patients will receive a total of
      4 suppositories.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Developed Post-ERCP Pancreatitis</measure>
    <time_frame>5 days</time_frame>
    <description>Assessment of whether patients developed post-ERCP pancreatitis, defined as a new onset of pain (or worsening of existing pain) in the upper abdomen, an elevation in pancreatic enzymes of at least three times the upper limit of the normal range 24 hours after the procedure, and hospitalization for at least two nights.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate or Severe Post-ERCP Pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <description>Assessment of whether patients developed either moderate or severe post-ERCP pancreatitis, defined according to established consensus criteria (Cotton et al., Gastrointestinal Endoscopy 1991;37:383-93). Severity of post-ERCP pancreatitis is partly defined according to length of stay. Moderate pancreatitis is defined as a 4-10 day hospitalization. Severe post-ERCP pancreatitis is defined as a hospitalization of greater than 10 days post-ERCP, or development of a complication (eg. pseudocyst or necrosis), or need for intervention (drainage or surgery).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1037</enrollment>
  <condition>Post-ERCP Pancreatitis</condition>
  <arm_group>
    <arm_group_label>high-dose indomethacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg rectal indomethacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dose indomethacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg rectal indomethacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose indomethacin</intervention_name>
    <description>patients randomized to this intervention receive 200mg indomethacin</description>
    <arm_group_label>high-dose indomethacin</arm_group_label>
    <other_name>Indocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard dose indomethacin</intervention_name>
    <description>patients randomized to this intervention receive 100mg indomethacin</description>
    <arm_group_label>standard dose indomethacin</arm_group_label>
    <other_name>Indocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Included patients are those undergoing Endoscopic Retrograde Cholangiopancreatography
        (ERCP) and have:

        one of the following:

          1. Clinical suspicion of sphincter of Oddi dysfunction (SOD; type I or II)

          2. History of post-ERCP pancreatitis (at least one episode)

          3. Pancreatic sphincterotomy

          4. Pre-cut (access) sphincterotomy

          5. greater than 8 cannulation attempts of any sphincter

          6. Pneumatic dilation of intact biliary sphincter

          7. Ampullectomy 8.) Assessment for post-sphincterotomy stenosis

        OR at least 2 of the following:

          1. Age less than 50 years old and female gender

          2. History of recurrent pancreatitis (at least 2 episodes)

          3. greater than or equal to to 3 pancreatic injections, with at least 1 injection to tail

          4. Pancreatic acinarization (excluding ventral pancreas of pancreas divisum)

          5. Pancreatic brush cytology -

        Exclusion Criteria:

          1. Unwillingness or inability to consent for the study

          2. Age less than 18 years

          3. Intrauterine pregnancy

          4. Breastfeeding mother

          5. Standard contraindications to ERCP

          6. Allergy/hypersensitivity to aspirin or Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

          7. Received NSAIDs in prior 7 days (aspirin 325mg or less ok)

          8. Renal failure (serum creatinine greater than 1.4)

          9. Active or recurrent (within 4 weeks) gastrointestinal hemorrhage

         10. Acute pancreatitis (lipase peak) within 72 hours

         11. Known chronic calcific pancreatitis

         12. Pancreatic head mass

         13. Procedure performed on major papilla/ventral pancreatic duct in patient with pancreas
             divisum (dorsal duct not attempted on injected)

         14. ERCP for biliary stent removal or exchange without anticipated pancreatogram

         15. Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy
             without anticipated pancreatogram

         16. Anticipated inability to follow protocol

         17. Known active cardiovascular or cerebrovascular disease -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan L Fogel, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Lukes' Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 29, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2013</study_first_posted>
  <results_first_submitted>April 25, 2019</results_first_submitted>
  <results_first_submitted_qc>May 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2019</results_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Evan Fogel</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>pancreatitis</keyword>
  <keyword>ERCP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT01912716/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between July 2013 - March 2018, either from the ERCP (Endoscopic Retrograde Cholangiopancreatography) outpatient clinic or Peri-Operative Care Unit immediately prior to ERCP.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>High-dose Indomethacin</title>
          <description>200mg rectal indomethacin
high dose indomethacin</description>
        </group>
        <group group_id="P2">
          <title>Standard Dose Indomethacin</title>
          <description>100mg rectal indomethacin
standard dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="522">receipt of 1st dose of indomethacin</participants>
                <participants group_id="P2" count="515"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Receipt of 2nd Dose</title>
              <participants_list>
                <participants group_id="P1" count="511"/>
                <participants group_id="P2" count="503"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>5-day Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
                <participants group_id="P2" count="515"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3-day Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="521"/>
                <participants group_id="P2" count="513"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
                <participants group_id="P2" count="515"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Dose Group</title>
          <description>Participants randomized to this group receive 100 mg indomethacin</description>
        </group>
        <group group_id="B2">
          <title>High Dose Group</title>
          <description>Participants randomized to this group receive 200 mg indomethacin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="515"/>
            <count group_id="B2" value="522"/>
            <count group_id="B3" value="1037"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="15.2"/>
                    <measurement group_id="B2" value="50.4" spread="15"/>
                    <measurement group_id="B3" value="49.9" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="392"/>
                    <measurement group_id="B2" value="421"/>
                    <measurement group_id="B3" value="813"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                    <measurement group_id="B2" value="507"/>
                    <measurement group_id="B3" value="1000"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="485"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="986"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="7.0"/>
                    <measurement group_id="B2" value="29.2" spread="7.6"/>
                    <measurement group_id="B3" value="28.9" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obese</title>
          <description>BMI greater than or equal to 30</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Suspicion of SOD (sphincter of Oddi dysfunction)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="319"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of post-ERCP pancreatitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of recurrent pancreatitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Difficult Cannulation</title>
          <description>greater than 8 attempts at cannulation of desired duct</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Precut sphincterotomy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Double-wire cannulation technique</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pancreatography (patients)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="446"/>
                    <measurement group_id="B2" value="433"/>
                    <measurement group_id="B3" value="879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of pancreatic duct injections</title>
          <units>injections</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.12" spread="1.63"/>
                    <measurement group_id="B2" value="1.96" spread="1.66"/>
                    <measurement group_id="B3" value="2.04" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Therapeutic pancreatic sphincterotomy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Placement of pancreatic stent</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="400"/>
                    <measurement group_id="B2" value="393"/>
                    <measurement group_id="B3" value="793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ampullectomy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biliary sphincterotomy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trainee involvement</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Post-ERCP Pancreatitis</title>
        <description>Assessment of whether patients developed post-ERCP pancreatitis, defined as a new onset of pain (or worsening of existing pain) in the upper abdomen, an elevation in pancreatic enzymes of at least three times the upper limit of the normal range 24 hours after the procedure, and hospitalization for at least two nights.</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard 100mg Dose</title>
            <description>patients receiving 100mg indomethacin</description>
          </group>
          <group group_id="O2">
            <title>High Dose 200 mg</title>
            <description>patients receiving 200mg indomethacin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Post-ERCP Pancreatitis</title>
          <description>Assessment of whether patients developed post-ERCP pancreatitis, defined as a new onset of pain (or worsening of existing pain) in the upper abdomen, an elevation in pancreatic enzymes of at least three times the upper limit of the normal range 24 hours after the procedure, and hospitalization for at least two nights.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate or Severe Post-ERCP Pancreatitis</title>
        <description>Assessment of whether patients developed either moderate or severe post-ERCP pancreatitis, defined according to established consensus criteria (Cotton et al., Gastrointestinal Endoscopy 1991;37:383-93). Severity of post-ERCP pancreatitis is partly defined according to length of stay. Moderate pancreatitis is defined as a 4-10 day hospitalization. Severe post-ERCP pancreatitis is defined as a hospitalization of greater than 10 days post-ERCP, or development of a complication (eg. pseudocyst or necrosis), or need for intervention (drainage or surgery).</description>
        <time_frame>30 days</time_frame>
        <population>development of moderate or severe post-ERCP pancreatitis</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose 100 mg</title>
            <description>patients receiving 100mg indomethacin</description>
          </group>
          <group group_id="O2">
            <title>High Dose 200mg</title>
            <description>patients receiving 200mg indomethacin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate or Severe Post-ERCP Pancreatitis</title>
          <description>Assessment of whether patients developed either moderate or severe post-ERCP pancreatitis, defined according to established consensus criteria (Cotton et al., Gastrointestinal Endoscopy 1991;37:383-93). Severity of post-ERCP pancreatitis is partly defined according to length of stay. Moderate pancreatitis is defined as a 4-10 day hospitalization. Severe post-ERCP pancreatitis is defined as a hospitalization of greater than 10 days post-ERCP, or development of a complication (eg. pseudocyst or necrosis), or need for intervention (drainage or surgery).</description>
          <population>development of moderate or severe post-ERCP pancreatitis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the length of the study, i.e. 5 years. Patients were recruited from July 2013 until March 2018. Following recruitment of the last patient (i.e. #1037), follow-up for an additional 30-day period was undertaken to capture severity of pancreatitis (should it occur) and delayed adverse events.</time_frame>
      <desc>In this study, there was no difference in definition of adverse events or serious adverse events, as other [not including serious] adverse events were not monitored/assessed. All patients provided contact information (home phone, cell phone, personal e-mail address) at study entry, and patients were then contacted at 5 and 30 days to assess for these adverse events, as noted in the study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard-dose Indomethacin</title>
          <description>100mg rectal indomethacin
standard dose indomethacin</description>
        </group>
        <group group_id="E2">
          <title>High-dose Indomethacin</title>
          <description>200mg rectal indomethacin
high-dose dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="515"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>pancreatitis</sub_title>
                <description>requiring hospitalization. Definition of post-ERCP pancreatitis was according to established consensus criteria (Cotton et al., Gastrointestinal Endoscopy 1991;37:383-93).</description>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="515"/>
                <counts group_id="E2" events="65" subjects_affected="65" subjects_at_risk="522"/>
              </event>
              <event>
                <sub_title>bleeding</sub_title>
                <description>as per consensus criteria (as noted for pancreatitis definition)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="515"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <description>increase in baseline serum creatinine, to greater than 1.4</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="522"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study took place at 6 tertiary medical centers in the United States. However, approximately 3/4 of patients were enrolled from a single site.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Evan Fogel</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-944-2816</phone>
      <email>efogel@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

